首页|期刊导航|Cancer Biology & Medicine|Unravelling the role of PANoptosis in diseases:from emerging molecular mechanisms-to-therapeutic implications

Unravelling the role of PANoptosis in diseases:from emerging molecular mechanisms-to-therapeutic implicationsOA

中文摘要

PANoptosis represents a distinct form of programmed cell death(PCD)that is characterized by the integration of key features from apoptosis,pyroptosis,and necroptosis but cannot be fully explained by any single cell death pathway.A key trigger of PANoptosis is the assembly and activation of the PANoptosome.To date,four types of PANoptosomes have been identified,including PANoptosomes nucleated by Z-DNA binding protein 1(ZBP1),absent in melanoma 2(AIM2),receptor-interacting protein kinase 1(RIPK1),and NOD-like receptor protein 12(NLRP12).This review summarizes current advances in the molecular regulatory mechanisms underlying PANoptosis and delineates the assembly and activation processes of several PANoptosome complexes.Furthermore,the role of PANoptosis in various pathologic conditions,such as infectious diseases,autoimmune disorders,neurodegenerative diseases,and cancer,are discussed.Recent preclinical and clinical advances in targeting the PANoptosis pathway through small molecule inhibitors,nanomedicines,and combination therapies for the treatment of infectious diseases,inflammatory conditions,and malignancies are also highlighted.However,current research involving the mechanisms underlying PANoptosis are preliminary and the clinical translation faces significant challenges,necessitating further in-depth exploration.This review demonstrates that targeting molecular components and signaling pathways of PANoptosis represents a highly promising therapeutic strategy,aiming to provide a theoretical foundation for the development of novel clinical treatments for related diseases.

Yi Zhu;Shengming Ou;Xuer Ye;Juncheng Li;Xiaoya Nie;Hongwei Shao;Rongxin Zhang;Jinrong Zhu

Department of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaSchool of Medicine,Jiaying University,Meizhou 514000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,ChinaDepartment of Oncology,First School of Clinical Medicine,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou 510000,China School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University,Guangzhou 510000,China

医药卫生

PANoptosisPANoptosomeimmunetargeted therapyclinical translation

《Cancer Biology & Medicine》 2026 (9)

P.1230-1249,20

supported by the Innovation Team Project in Regular Colleges and Universities of Guangdong Province[natural science](Grant No.2023KCXTD021)the Natural Science Foundation of Guangdong Province(Grant No.2025A1515010265)the Medical Science and Technology Research Foundation of Guangdong Province(Grant No.A2024066)the Characteristic Innovation Project of General Colleges and Universities in Guangdong Province(Grant No.2025KTSCX060).

10.20892/j.issn.2095-3941.2026.0012

评论